Yu, Elaine W Tsourdi, Elena Clarke, Bart L Bauer, Douglas C Drake, Matthew T
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is th...
Yu, Elaine W Tsourdi, Elena Clarke, Bart L Bauer, Douglas C Drake, Matthew T
Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is th...
Cosman, Felicia McMahon, Donald Dempster, David Nieves, Jeri W
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
In the absence of an intervening antiresorptive agent, cyclic administration of teriparatide does not increase bone mineral density (BMD) more than standard daily therapy. Because denosumab is a potent antiresorptive agent with a rapid off-effect, we hypothesized that it might be the optimal agent to help maximize bone gains with cyclic teriparatid...
Mori, Takahiro Crandall, Carolyn J Ganz, David A
Published in
JBMR Plus
Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture. Because market exclusivity for brand teriparatide expired in August 2019 in the US, we sought to understand the potential health economic impact of the availabi...
Mori, Takahiro Crandall, Carolyn J Ganz, David A
Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture. Because market exclusivity for brand teriparatide expired in August 2019 in the US, we sought to understand the potential health economic impact of the availabi...
Lorentzon, Mattias Branco, Jaime Brandi, Maria Luisa Bruyère, Olivier Chapurlat, Roland Cooper, Cyrus Cortet, Bernard Diez-Perez, Adolfo Ferrari, Serge Gasparik, Andrea
...
Published in
Advances in therapy
Increased biochemical bone turnover markers (BTMs) measured in serum are associated with bone loss, increased fracture risk and poor treatment adherence, but their role in clinical practice is presently unclear. The aim of this consensus group report is to provide guidance to clinicians on how to use BTMs in patient evaluation in postmenopausal ost...
Schmidt, Tobias Rolvien, Tim Linke, Carolin Jandl, Nico Maximilian Oheim, Ralf Amling, Michael Barvencik, Florian
Published in
JBMR Plus
The response to teriparatide has been described in very few cases of hypophosphatasia (HPP). In this cross‐sectional study, we report the prevalence of symptomatic bone marrow edema (BME) and fracture healing complications in a large cohort of childhood and adult HPP patients and discuss the results of teriparatide treatment in four cases. From 201...
Peugh, Jennifer Khalil, Andrew Chan, Micah R Hansen, Karen E
Published in
JBMR plus
Hypercalcemia most often results from primary hyperparathyroidism and malignancy. Adynamic bone disease (ABD) is a form of renal osteodystrophy characterized by reduced bone turnover, which can limit the ability of bone to release or store calcium, potentially leading to low, normal, or high serum calcium levels. We describe a 51-year-old dialysis-...
Paschalis, Eleftherios P Krege, John H Gamsjaeger, Sonja Eriksen, Erik F Burr, David B Disch, Damon P Stepan, Jan J Fahrleitner-Pammer, Astrid Klaushofer, Klaus Marin, Fernando
...
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Teriparatide increases bone mass primarily through remodeling of older or damaged bone and abundant replacement with new mineralizing bone. This post hoc analysis investigated whether dual-energy X-ray absorptiometric (DXA) areal bone mineral density (aBMD) measurement adequately reflects changes of mineral and organic matrix content in cortical an...
Niimi, Rui Kono, Toshibumi Nishihara, Atsushi Hasegawa, Masahiro Kono, Toshihiko Sudo, Akihiro
Published in
JBMR plus
There is no consensus on an optimal treatment after daily teriparatide (TPTD). We performed a prospective, randomized, open-label, 12-month trial to investigate the efficacy of follow-up treatment after daily TPTD treatment for Japanese patients. Three-hundred patients were enrolled in this study. Patients received oral bisphosphonate (BP) includin...
